OBJECTIVES: To determine the oncological impact and adverse events of performing simultaneous transurethral resection of bladder tumour (TURB) and transurethral resection of the prostate (TURP), as evidence on the outcomes of simultaneous TURB for bladder cancer and TURP for obstructive benign prostatic hyperplasia is limited and contradictory. PATIENTS AND METHODS: Patients from 12 European hospitals treated with either TURB alone or simultaneous TURB and TURP (TURB+TURP) were retrospectively analysed. A propensity score matching (PSM) 1:1 was performed with patients from the TURB+TURP group matched to TURB-alone patients. Associations between surgery approach with recurrence-free (RFS) and progression-free (PFS) survivals were assessed in Cox regression models before and after PSM. We performed a subgroup analysis in patients with risk factors for recurrence (multifocality and/or tumour size >3 cm). RESULTS: A total of 762 men were included, among whom, 76% (581) underwent a TURB alone and 24% (181) a TURB+TURP. There was no difference in terms of tumour characteristics between the groups. We observed comparable length of stay as well as complication rates including major complications (Clavien-Dindo Grade ≥III) for the TURB-alone vs TURB+TURP groups, while the latest led to longer operative time (P < 0.001). During a median follow-up of 44 months, there were more recurrences in the TURB-alone (47%) compared to the TURB+TURP group (28%; P < 0.001). Interestingly, there were more recurrences at the bladder neck/prostatic fossa in the TURB-alone group (55% vs 3%, P < 0.001). TURB+TURP procedures were associated with improved RFS (hazard ratio [HR] 0.39, 95% confidence interval [CI] 0.29-0.53; P < 0.001), but not PFS (HR 1.63, 95% CI 0.90-2.98; P = 0.11). Within the PSM cohort of 254 patients, the simultaneous TURB+TURP was still associated with improved RFS (HR 0.33, 95% CI 0.22-0.49; P < 0.001). This was also true in the subgroup of 380 patients with recurrence risk factors (HR 0.41, 95% CI 0.28-0.62; P < 0.001). CONCLUSION: In our contemporary cohort, simultaneous TURB and TURP seems to be an oncologically safe option that may, even, improve RFS by potentially preventing disease recurrence at the bladder neck and in the prostatic fossa.
- MeSH
- hyperplazie prostaty * komplikace MeSH
- lidé MeSH
- lokální recidiva nádoru patologie MeSH
- nádory močového měchýře * patologie MeSH
- prostata chirurgie patologie MeSH
- retrospektivní studie MeSH
- transuretrální resekce prostaty * škodlivé účinky metody MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
European urology supplements, ISSN 1569-9056 ; vol. 7, no. 1, February 2008
34 s. : il., tab. ; 28 cm
- MeSH
- management nemoci MeSH
- mezioborová komunikace MeSH
- nádory prostaty terapie MeSH
- Publikační typ
- sborníky MeSH
- Konspekt
- Patologie. Klinická medicína
- NLK Obory
- urologie
- onkologie
Urology, ISSN 0090-4295 ; vol. 68, suppl. 3A, September 2006
60 s. : il., tab. ; 28 cm
- MeSH
- erektilní dysfunkce farmakoterapie MeSH
- inhibitory fosfodiesteras farmakokinetika farmakologie terapeutické užití MeSH
- Publikační typ
- sborníky MeSH
- Konspekt
- Farmacie. Farmakologie
- NLK Obory
- sexuologie
- urologie
- farmacie a farmakologie
EAU update series, ISSN 1570-9124 ; vol. 2, no. 2, June 2004
42-92 s. : tab., il. ; 28 cm
- MeSH
- erekce penisu účinky léků MeSH
- erektilní dysfunkce MeSH
- nemoci koronárních tepen MeSH
- prostatektomie MeSH
- Publikační typ
- sborníky MeSH
- Konspekt
- Patologie. Klinická medicína
- NLK Obory
- urologie
- andrologie
European urology supplements, ISSN 1569-9056 ; vol. 1, no. 3, suppl., May 2002
37 s. : il., tab. ; 28 cm
- MeSH
- agonisté dopaminu terapeutické užití MeSH
- aplikace sublinguální MeSH
- erektilní dysfunkce farmakoterapie MeSH
- management nemoci MeSH
- morfin - deriváty aplikace a dávkování farmakokinetika terapeutické užití MeSH
- Publikační typ
- sborníky MeSH
- Konspekt
- Patologie. Klinická medicína
- NLK Obory
- urologie
- farmacie a farmakologie
International journal of impotence research, ISSN 0955-9930 ; vol. 13, suppl. 4, October 2001
S54 s. ; 30 cm
- MeSH
- erektilní dysfunkce MeSH
- muži MeSH
- sexuální dysfunkce fyziologická MeSH
- ženy MeSH
- Publikační typ
- abstrakty MeSH
- kongresy MeSH
- Konspekt
- Patologie. Klinická medicína
- NLK Obory
- andrologie
- sexuologie